| Patient | Ada Lovelace |
|---|---|
| Date of birth | 1990-12-10 |
| Identifiers | MRN HR-NI031-SYN; SSN (made up) 000-31-6729 |
| Document date | 2026-07-07 |
| Author | Constance Whitley-Adeyemi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
No bowel movement for five days, with bloating and cramps. [S]
Mrs. Lovelace asked for a same-day visit. She had her first cycle of carboplatin, paclitaxel and pembrolizumab a week ago and took ondansetron twice a day for three days after it. She takes long-acting morphine 15 mg twice a day, with one or two 5 mg doses of the oral solution on some days, senna two tablets at night and polyethylene glycol once a day, though she missed some doses of the laxatives while she felt sick. She has not opened her bowels for five days. She feels bloated with cramping in the lower abdomen, but she is passing wind, has not vomited, and is eating a little. She has no fever. The vaginal bleeding has stopped since the radiation. Her pelvic pain is no worse. [S]
| Element | Detail |
|---|---|
| Onset | No bowel movement since five days ago |
| Location | Lower abdomen |
| Duration | Five days |
| Character | Bloating and cramping |
| Severity | Cramps 4 of 10 |
| Timing | Constant bloating; intermittent cramps |
| Context | First chemotherapy cycle a week ago; ondansetron for three days; long-acting morphine; missed laxative doses |
| Modifying factors | Passing wind eases the cramps |
| Associated signs and symptoms | Mild nausea; no vomiting, fever, or bleeding |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or chills |
| Gastrointestinal | Positive | No stool for five days, bloating, cramps, mild nausea; passing wind; no vomiting or blood |
| Genitourinary | Negative | No vaginal bleeding; passing urine normally |
| Neurological | Negative | No confusion or drowsiness |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain | 0.5 mL four to six times a day as needed | Oral route | 2024-06-03 to 2026-06-02 | completed | S |
| Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain | 5 mg every 4 hours as needed | Oral route | 2026-06-02 | active | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole | every 12 hours | Oral route | 2026-06-16 to 2026-10-20 | completed | S |
| Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 | one spray as needed for suspected overdose; repeat after 2 to 3 minutes if needed | Nasal route | 2026-06-02 | active | S |
| Senna 8.6 mg tablet, two tablets by mouth at night | two tablets at night | Oral route | 2026-06-02 | active | S |
| Polyethylene glycol 3350, 17 g in water by mouth once or twice a day | once daily, up to twice daily | Oral route | 2026-06-02 | active | S |
| Acetaminophen 500 mg tablet, two tablets by mouth three times a day | 1 g three times a day | Oral route | 2026-06-02 | active | S |
| Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits | 750 mg on two occasions two weeks apart | Intravenous route | 2026-06-02 to 2026-06-17 | completed | S |
| Pembrolizumab 200 mg intravenously every 3 weeks | every 3 weeks | Intravenous route | 2026-06-30 | active | S |
| Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles | every 3 weeks for six cycles | Intravenous route | 2026-06-30 to 2026-10-13 | completed | S |
| Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication | every 3 weeks for six cycles | Intravenous route | 2026-06-30 to 2026-10-13 | completed | S |
| Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed | twice a day for three days after each cycle, then as needed | Oral route | 2026-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-07 | Body height | 165 | cm | S |
| 2026-07-07 | Body weight | 53.8 | kg | S |
| 2026-07-07 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-07-07 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-07-07 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-07-07 | Heart rate | 88 | /min | S |
| 2026-07-07 | Respiratory rate | 16 | /min | S |
| 2026-07-07 | Body temperature | 36.7 | Cel | S |
| 2026-07-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-07 | Potassium [Moles/volume] in Serum or Plasma | 3.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-07 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
Vital signs recorded on 2026-07-07; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Comfortable at rest; temperature 36.7 C, blood pressure 110/70, pulse 88 |
| Abdomen | Mildly distended and soft, with active bowel sounds; mild tenderness in the left lower quadrant over palpable stool; no guarding, rebound, or tympanic distension |
| Mental status | Alert and clear; pupils normal size; not sedated |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake | resolved | confirmed | N93.8 | S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding anchored to her documented final illness. |
| Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis | active | confirmed | C53.0 | S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice. |
| Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension | active | confirmed | G89.3 | S — Synthetic modern diagnosis made at the second visit. |
| Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied | active | confirmed | Z79.891 | S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing. |
| Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxatives | resolved | confirmed | K59.03 | S — Synthetic adverse drug effect; not a historical claim. |
Guideline basis: Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023)
Follow-up: Telephone check in two days. Six-week review next week. Next scheduled visit 2026-07-14: six-week review: bleeding and pain after palliative pelvic radiation, the first cycle of chemotherapy with pembrolizumab, blood counts, mood and opioid safety. [S]